Prophylactic Efmoroctocog Alfa may improve outcomes in patients with hemophilia A: Study

Among the 545 patients included in the analysis, Elocta® emerged as the most frequently utilized treatment option. The bleeding events affected 15.4% of patients, while 13.9% experienced articular non-bleeding events leading to hospitalization. The surgeries or procedures related to hemophilic arthropathy were reported in 9.9% of cases. The outcomes revealed a mean monthly factor VIII product consumption of 344 IU/kg/month for extended half-life treatment and 331 IU/kg/month for standard half-life products.

The sub-cohort analysis involved a total of 146 patients who transitioned to Elocta® observed promising trends. Although bleeding events did not significantly decrease post-switch, there was a marked reduction in their frequency. Also, bleeding events decreased from a mean of 0.32 events per patient per year to 0.09 events post-switch. Importantly, this reduction did not reach statistical significance. There were no significant differences in factor consumption rates or the occurrence of articular non-bleeding events before and after the initiation of Elocta®. Overall, this study provides valuable insights into the treatment landscape and clinical outcomes for the patients with hemophilia A who are receiving prophylactic regimens in France. 

Source: 

Trossaërt, M., Falk, A., Gautier, L., Kragh, N., Van Hinloopen, O., & Varin, R. (2024). An observational study of haemophilia A patients without inhibitors using the French national claims (SNDS) database. In Hematology (Vol. 29, Issue 1). Informa UK Limited. https://doi.org/10.1080/16078454.2024.2320610